glp-1 muscle Glucagon-like peptide-1 receptor agonists and mass effects Weighing the risk of GLP-1

There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.

By slowing digestion and promoting a feeling of fullness, semaglutide helps individuals consume fewer calories without feeling deprived

Drinking on GLP-1s can feel different

GLP-1 receptor agonists like semaglutide require special evaluation and approval before use

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

report here on a GIPR antagonist conjugated to GLP-1 analogues that reduces body weight and improves metabolic markers in preclinical and phase 1 clinical settings.